Tag: safety

Châtillon, France, le 12 juin (22:30 CEST) 2025

Châtillon, France, June 12, 2025

PARAMUS, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, announced today Gabrail Cancer Center (GCC) in Canton, Ohio is now activated and open for enrolling patients in its Phase 2a clinical trial evaluating their continuous low-dose lenalidomide, STAR-LLD, for the treatment of multiple myeloma (MM). Dr. Nash Gabrail, medical oncologist and founder of the Center, is the study’s lead investigator. Regional Medical Oncology Center, located in Wilson, NC, has also opened as the trial’s second active clinical site.

Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals” or the “Company”) (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”).

Kraken’s Founder Mr. Boone Smith’s extensive experience and work at U.S. Dept of Homeland Security and U.S. Customs and Border Protection adds the necessary team capabilities to assist the Company’s border security solutions effort

Company Announcement

RIYADH, Saudi Arabia, June 12, 2025 (GLOBE NEWSWIRE) -- In a medical achievement considered the first of its kind in the region, King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh has successfully performed an endoscopic sleeve gastroplasty (ESG) on a patient who had previously undergone a kidney transplant, a case that requires meticulous management of immunosuppressive medications and the prevention of any complications that could jeopardize the transplanted organ. This procedure marks a significant advancement in providing safe treatment solutions for transplant recipients, to improve their graft survival and quality of life.